SCHEMBL13027243

SCHEMBL13027243

CSCC[C@H](NC(=O)[C@@H](NC(=O)COCCOCCNC(O)COCCOCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RAMP3 O60896 9/20 0.62
CALCR P30988 9/20 0.62
GLP1R P43220 3/20 0.51
GCGR P47871 3/20 0.51
IL23R Q5VWK5 1/20 0.51
MC4R P32245 1/20 0.50
MC5R P33032 1/20 0.50
MC3R P41968 1/20 0.50
MC1R Q01726 1/20 0.50
CXCR4 P61073 2/20 0.50
PRLHR P49683 2/20 0.49
TFPI P10646 1/20 0.49
APLNR P35414 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12984102 0.97 RAMP3 (0.66) RAMP3CALCRGLP1RGCGRIL23R
SCHEMBL12984646 0.85 RAMP3 (0.63) RAMP3CALCRTFPIAPLNR
SCHEMBL13028975 0.82 RAMP3 (0.65) RAMP3CALCRMC4RMC5RMC3R
SCHEMBL31332016 0.79 MC4R (0.71) GLP1RMC4RMC5RMC3RMC1R
SCHEMBL22423719 0.78 RAMP3 (0.56) RAMP3CALCRGLP1RGCGRIL23R
SCHEMBL14096140 0.78 RAMP3 (0.60) RAMP3CALCRMC4RMC5RMC3R
Angiotensin Amide SCHEMBL4448793 0.77 AGTR2 (0.63) RAMP3CALCRTFPI
SCHEMBL10065713 0.76 RAMP3 (0.61) RAMP3CALCRTFPI
SCHEMBL30439961 0.76 C5AR1 (0.55) CALCRGLP1RGCGRMC4RAPLNR
SCHEMBL10065712 0.76 PLG (0.47) IL23R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100316563-A1 Method For The Preparation Of New Oligoclonal Antibodies BRACCO IMAGING S.P.A. (IT) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316563-A1 Method For The Preparation Of New Oligoclonal Antibodies APOB, APOL1, FCGR3B RAMP3 3589/4885CALCR 1054/4885GLP1R 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.